摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methyl-pyrazolo[1,5-a]pyrazine | 53902-77-5

中文名称
——
中文别名
——
英文名称
4-methyl-pyrazolo[1,5-a]pyrazine
英文别名
4-Methylpyrazolo[1,5-a]pyrazine;4-methylpyrazolo[1,5-a]pyrazine
4-methyl-pyrazolo[1,5-<i>a</i>]pyrazine化学式
CAS
53902-77-5
化学式
C7H7N3
mdl
——
分子量
133.153
InChiKey
ZSBSNUPQOCWLLL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • [EN] METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'OREXINE DE TYPE MÉTHYL-DIAZÉPANE
    申请人:MERCK SHARP & DOHME
    公开号:WO2016085784A1
    公开(公告)日:2016-06-02
    The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及甲基二氮杂环己烷化合物,其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在的治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进睡眠的疾病中的用途。
  • CXCR7 ANTAGONISTS
    申请人:ChemoCentryx, Inc.
    公开号:US20140154179A1
    公开(公告)日:2014-06-05
    Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    提供具有化学式I的化合物,或其药用可接受的盐、合物或N-氧化物,并且这些化合物可用于与CXCR7结合,治疗部分或完全依赖于CXCR7活性的疾病。因此,根据本发明的进一步方面,提供含有上述化合物之一或多个的组合物与药用可接受的赋形剂混合物。
  • METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS
    申请人:KUDUK SCOTT D.
    公开号:US20170305916A1
    公开(公告)日:2017-10-26
    The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
  • 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS
    申请人:Kim Ronald M.
    公开号:US20170320874A1
    公开(公告)日:2017-11-09
    The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
  • US9169261B2
    申请人:——
    公开号:US9169261B2
    公开(公告)日:2015-10-27
查看更多